Crossmark

Status and perspectives of acute stroke care in Europe

Crossref DOI link: https://doi.org/10.1007/s10072-018-3675-9

Published Online: 2018-12-07

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caso, Valeria https://orcid.org/0000-0002-2020-8891
de Sousa, Diana Aguiar

Fischer, Urs
License Information

Text and Data Mining valid from 2018-12-07
More Information

Article History

Received: 19 October 2018

Accepted: 2 December 2018

First Online: 7 December 2018

Compliance with ethical standards

:

: Dr. Fischer is a Consultant for Medtronic, Stryker and Commonwealth Serum Laboratories Behring. He is a principal investigator of the SWITCH (Swiss Trial of Decompressive Craniectomy Versus Best.Medical Treatment of Spontaneous Supratentorial Intracerebral Hemorrhage (SWITCH): A Randomised Controlled Trial), ELAN (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation: An International Multicenter, Randomised-Controlled, Two-Arm, Assessor-Blinded Trial), and SWIFT DIRECT trial (Solitaire With the Intention for Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire Stent-Retriever Thrombectomy in Acute Anterior Circulation Stroke).Dr. Caso receives Advisory board fee for Respect-ESUS. All fees and speaker fees for Bayer, Boehringer Ingelheim, BMS-Pfizer, Ever-Neuropharma are paid to ARS UMBRIA.